TY - JOUR
T1 - Endocrine changes in Alzheimer's disease
AU - Davidson, M.
AU - Bastiaens, L.
AU - Davis, B. M.
AU - Shah, M. B.
AU - Davis, K. L.
PY - 1988
Y1 - 1988
N2 - At present, no consistent endocrine abnormalities can be detected in patients suffering from Alzheimer's disease. However, assessment of neuroendocrine function might help identify subpopulations of patients with particular neurotransmission abnormalities who are likely to benefit from a specific pharmacologic strategy. For example, patients in whom cholinomimetic drugs produce the greatest elevation in plasma cortisol concentration appear to derive the most symptomatic benefit from these drugs.
AB - At present, no consistent endocrine abnormalities can be detected in patients suffering from Alzheimer's disease. However, assessment of neuroendocrine function might help identify subpopulations of patients with particular neurotransmission abnormalities who are likely to benefit from a specific pharmacologic strategy. For example, patients in whom cholinomimetic drugs produce the greatest elevation in plasma cortisol concentration appear to derive the most symptomatic benefit from these drugs.
UR - http://www.scopus.com/inward/record.url?scp=0023905590&partnerID=8YFLogxK
U2 - 10.1016/s0889-8529(18)30438-9
DO - 10.1016/s0889-8529(18)30438-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:0023905590
SN - 0889-8529
VL - 17
SP - 149
EP - 157
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
IS - 1
ER -